At least four of six different vaccine candidates financially backed by the U.S. government aimed at the novel coronavirus are predicted to fail in the clinic, according to a draft report from an analytics group cited by CNBC.
AstraZeneca’s Covid-19 vaccine candidate begins late-stage U.S. study
"Operation Warp Speed" Initiative, Brazil, Britain, Clinical Trials, Coronavirus Infections, Covid-19 Data, COVID-19 Vaccines, Elections, Emergency Departments, Japan, National Institutes of Health, Novel Coronavirus, Oxford University, Placebo, R&D, Russia, South Africa, StudiesAstraZeneca Plc has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of the company’s high-profile Covid-19 vaccine candidate.
The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.
Top U.S. health official says approval of COVID vaccines unlikely before November
"Operation Warp Speed" Initiative, Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, Donald Trump, FDA/Regulatory, Health Officials, National Institutes of Health, R&D, Trump Administration, U.S. government, United States(Reuters) – Any potential COVID-19 vaccine backed by the Trump administration’s “Operation Warp Speed” program is unlikely to receive a green light from regulators any earlier than November or December, […]
The United States entered an agreement with drugmaker Moderna Inc. to acquire 100 million doses of the company’s potential COVID-19 vaccine for around $1.5 billion, the company and White House said.
Omeros’ COVID-19 treatment shows promise, shares jump
"Operation Warp Speed" Initiative, Acute Respiratory Distress Syndrome (ARDS), Breakthrough Status, Business, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Hospitals, Italy, Monoclonal Antibodies, R&D, Shares, Stem Cell Transplant, U.S. governmentOmeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a Covid-19 vaccine candidate under development by the two companies.
NIH Pushing Large-Scale, Organized COVID-19 Trials
"Operation Warp Speed" Initiative, Blood Clots, Blood Thinner, Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, Cytokines, Hospitalized COVID-19 Patients, Immune System, Monoclonal Antibodies, National Institutes of Health, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.
Report: AstraZeneca’s Covid-19 Vaccine Generates Antibodies and T-Cells Against the Virus in Phase I Trial
"Operation Warp Speed" Initiative, Antibodies, Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, Data, Oxford University’s Jenner Institute, R&D, Shares, T-Cells, The Lancet, The Telegraph, United KingdomPhase I data from the Covid-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
Life sciences company IQVIA Holdings Inc. will collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.